Long-Acting, Injectable Male Contraceptive Proven Efficient for a Minimum of 2 Years, Claims Biotechnology Entrepreneurship
A New Era for Male Contraception: Contraline's ADAM Clinical Trials Reach Crucial Milestone
It's about bloody time! Men now have a shot at a non-hormonal, long-lasting reversible contraceptive, thanks to Contraline's revolutionary breakthrough. Their male contraceptive, ADAM, has just reached a significant milestone in its first human clinical trial, lasting two years now. You heard it right! Two entire years of testosterone-fueled freedom without fertilizing any egg.
In an overwhelmingly pubescent press release, Contraline announced that ADAM, their water-soluble hydrogel injected into the vasa deferentia, has proven safe and effective. Although they haven't released their official clinical results in a scientific journal yet, the bigwigs over at Contraline will drop additional data at the American Urological Association (AUA) meeting on April 26.
The ADAM implant stops sperm without killing the mood, allowing guys to maintain their shag-worthy performance, all while ensuring no unwanted bundles of joy pop up. Contraline is positioning ADAM as a futuristic, long-term, and reversible contraceptive alternative to condoms and vasectomies.
According to Alexander Pastuszak, Contraline's Chief Medical Officer, "ADAM's findings have confirmed our goal of delivering a male contraceptive lasting a full two years. With its safety, efficacy, and reversibility, we're optimistic that this baby (or rather, no-baby) maker could give men and partners greater sexual freedom."
ADAM has accomplished a zero-sperm act in two participants during the clinical trial, a result that screams success. Back in the day, Contraline claimed that ADAM reduced the moving sperm count by 99.8% to 100% within 30 days of implantation, suggesting it packs a punch similar to long-acting female contraceptives like IUDs.
The pioneers over at Contraline are hopeful that guys will find ADAM a "no brainer" when considering contraceptive options. For those unaware, IUDs are small, female, long-lasting contraceptive devices inserted into the uterus for convenience.
Mild but important shoutout to the participants who took part in the clinical trial. No serious adverse events have been reported, and they've all been fed sausages and beer to make up for their minor inconveniences. Researchers will continue monitoring other participants across the 12-, 15-, 18-, and 21-month milestones through lab and at-home sperm testing.
One grouchy professor, Jon Oatley, from Washington State University, poked holes in Contraline's work. He pointed out the lack of data confirming ADAM's reversibility and questioned the long-term effects of blocking the vasa deferentia. Still, he admitted that most guys might prefer a contraceptive pill or patch over a surgery.
Nevertheless, let's take a look at the numbers from 2017 to 2019. A staggering 10.4% of women between the ages of 15 and 49 used long-acting reversible contraceptives like IUDs and other implants. This is slightly less than the 14% who opted for the pill. If ADAM delivers on its promise of safety and effectiveness, it could persuade a substantial number of guys to choose long-term precision over short-term ammunition.
In conclusion, ADAM brings us one step closer to the future of male contraception. However, long-term studies will provide the final verdict on its safety, efficacy, and reversibility. So, fellas, brace yourselves because you might need to be more involved in the contraceptive conversation. 🤪👨🦲😍
- The revolutionary breakthrough in male contraceptive technology by Contraline, ADAM, has achieved a significant milestone in its two-year clinical trial.
- Contraline's ADAM, a water-soluble hydrogel, has been injected into the vasa deferentia and shown to be safe and effective thus far.
- The future of male contraception could see a shift towards long-lasting, reversible methods, with Contraline positioning ADAM as an alternative to condoms and vasectomies.
- Alexander Pastuszak, Contraline's Chief Medical Officer, expressed optimism about ADAM's potential to provide men and partners with greater sexual freedom.
- In the clinical trial, ADAM successfully achieved a zero-sperm act in two participants, suggesting similar efficacy to long-acting female contraceptives like IUDs.
- The science and health-and-wellness communities are keeping a close eye on ADAM's development, with men's health and sexual health particularly interested in its potential success.
- As research continues, regulatory bodies will monitor the safety, efficacy, and reversibility of ADAM, with the American Urological Association (AUA) meeting on April 26 providing vital additional data.
